Moderna Vaccine ‘Hits the Mark’ as Street Sees a Blockbuster
- Goldman assigns Wall Street-high price target of $105
- Another analyst predicts $10 billion in annual vaccine sales
Photographer: Adam Glanzman/Bloomberg
This article is for subscribers only.
Moderna Inc. got a new Wall Street-high price target from Goldman Sachs as its shares traded at a record after the biotech company revealed positive early results from its experimental vaccine for Covid-19.
An initial look at mRNA-1273, as the inoculation is known, “hits the mark,” analyst Salveen Richter said, raising her price target to $105 from $63, or 27% above the prior Street high of $83. Richter rates Moderna a buy. Piper Sandler analysts soon followed raising their price target to $102 from $57 saying Moderna could have “potential blockbuster vaccine sales next year.”